Formoterol inhalation - Mylan Specialty
Alternative Names: Formoterol fumarate inhalation solution - Mylan Specialty; Nebulised formoterol fumarate - Mylan Specialty; Perforomist; Perforomist Inhalation SolutionLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Dey LP
- Developer Mylan Specialty
- Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 23 Jun 2021 First Generic equivalent available in USA for Chronic obstructive pulmonary disease
- 17 Apr 2015 The United States Court of Appeals for the Federal Circuit upholds Mylan's U.S. Patents on formoterol inhalation solution
- 19 May 2009 Pooled efficacy & adverse events data from 2 phase III trials in Chronic obstructive pulmonary disease presented at the 105th International Conference of the American Thoracic Society (ATS-2009)